RE:RE:RE:RE:CD8+ TiLs and T-cell exhaustionNeither BioNTech or Pfizer will allow their mRNA vaccine knowledge & manufacturing capacity languish into oblivion. Instead both companies will be transitioning into therapeutic technologies like oncolytic virus that complement their RNA vaccine knowledge and manufacturing/distribution superiority.
More specifically Pfizer/BioNTech will seek to acquire late stage development cancer companies with RNA based biological products, like ONCY's platform drug pelareorep, which is directly positioned to facilitate their transition to the cancer sector, with pelareorep being able to "bolt-on" to potential acquirers' product portfolios that will allow these Big Pharma/BioPharma/Biotech companies to go beyond mRNA Covid-19 vaccine enterrpises, while maintaining their inherent knowledge, know-how and technological capacities in the "vaccine" development arena.